Testing effectiveness (Phase 2)Study completedNCT00705315
What this trial is testing
Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer
Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 46